The Center for Biosimilars® recaps the top 5 articles for the week of August 6, 2018.
Transcript:
Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of August 6.
Number 5: Stada recently announced that it is increasing its presence in the biosimilar sphere by becoming the majority shareholder in Bioceuticals, a venture capital-funded organization created by Stada to carry out its biosimilar programs.
Number 4: Full results of a 30-week study of Pfizer’s biosimilar infliximab, Ixifi, in patients with rheumatoid arthritis show the product has similar efficacy to Remicade, with or without dose escalation.
Number 3: The United Kingdom has proposed extending price controls to biosimilars. The measures require brand-name drug makers to pay the government 7.8% of their sales of products to the National Health Service.
Number 2: The Initiative for Medicines, Access, and Knowledge has issued a new report that calls out drug makers for securing large numbers of patents—and raising prices—on high-cost drugs.
Number 1: Celltrion’s troubled manufacturing plant is the subject of yet another FDA Form 483.
Finally, last week, our e-newsletter asked whether Congress should pass newly introduced legislation requiring innovator and biosimilar sponsors to disclose the terms of agreements that delay biosimilar market entry.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Biosimilars Regulatory Roundup for September 2023—Podcast Edition
October 1st 2023On this episode, we discuss several regulatory updates from around the globe, including some European and Japanese approvals, the FDA’s 2-day workshop on the present science behind clinical efficacy testing for biosimilars, and streamlining biosimilar development.
Part 3: Study Questions Usefulness of Clinical Efficacy Trials for Oncology Biosimilars in Europe
November 16th 2023In part 3 of a 3-part series for Global Biosimilars Week, The Center for Biosimilars® reviews an analysis investigating whether clinical efficacy studies have an impact on prescribing decisions for oncology biosimilars across Europe.